Compass Therapeutics, Inc. (CMPX) stock
CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.83−0.01 (-0.93%)
Close on Nov 11, 2026Market cap $149.51MP/E –Yield –
Compass Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Compass Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $68.68M, up 24.1% year over year. For fiscal 2025 it was $55.97M, up 32.2% from the year before. The highest annual figure on record is $55.97M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.97M | +32.2% |
| FY2024 | Dec 31, 2024 | $42.34M | +11.1% |
| FY2023 | Dec 31, 2023 | $38.12M | +27.1% |
| FY2022 | Dec 31, 2022 | $30.00M | +47.5% |
| FY2021 | Dec 31, 2021 | $20.34M | +36.5% |
| FY2020 | Dec 31, 2020 | $14.90M | -33.6% |
| FY2019 | Dec 31, 2019 | $22.45M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $22.04M | +71.8% |
| Q2 FY2026 | Jun 30, 2026 | $19.58M | +19.3% |
| Q1 FY2026 | Mar 31, 2026 | $13.39M | +2.6% |
| Q4 FY2025 | Dec 31, 2025 | $13.67M | +4.9% |
| Q3 FY2025 | Sep 30, 2025 | $12.83M | +48.9% |
| Q2 FY2025 | Jun 30, 2025 | $16.42M | +46.9% |
| Q1 FY2025 | Mar 31, 2025 | $13.05M | +37.1% |
| Q4 FY2024 | Dec 31, 2024 | $13.04M | +4.9% |
| Q3 FY2024 | Sep 30, 2024 | $8.61M | -2.5% |
| Q2 FY2024 | Jun 30, 2024 | $11.17M | +9.3% |
| Q1 FY2024 | Mar 31, 2024 | $9.52M | +43.4% |
| Q4 FY2023 | Dec 31, 2023 | $12.43M | +25.2% |
| Q3 FY2023 | Sep 30, 2023 | $8.83M | -9.8% |
| Q2 FY2023 | Jun 30, 2023 | $10.22M | +74.4% |
| Q1 FY2023 | Mar 31, 2023 | $6.64M | +50.4% |
| Q4 FY2022 | Dec 31, 2022 | $9.93M | +3.7% |
| Q3 FY2022 | Sep 30, 2022 | $9.79M | +210.4% |
| Q2 FY2022 | Jun 30, 2022 | $5.86M | +101.8% |
| Q1 FY2022 | Mar 31, 2022 | $4.42M | -6.1% |
| Q4 FY2021 | Dec 31, 2021 | $9.57M | +117.3% |
| Q3 FY2021 | Sep 30, 2021 | $3.15M | -14.1% |
| Q2 FY2021 | Jun 30, 2021 | $2.91M | -2.7% |
| Q1 FY2021 | Mar 31, 2021 | $4.70M | +31.7% |
| Q4 FY2020 | Dec 31, 2020 | $4.41M | -26.3% |
| Q3 FY2020 | Sep 30, 2020 | $3.67M | -70.9% |
| Q2 FY2020 | Jun 30, 2020 | $2.99M | – |
| Q1 FY2020 | Mar 31, 2020 | $3.57M | – |
| Q2 FY2019 | Sep 30, 2019 | $5.98M | – |
| Q1 FY2019 | Jun 30, 2019 | $12.63M | – |
See a number that looks wrong?